Clinical Research Directory
Browse clinical research sites, groups, and studies.
Autoimmunity After Checkpoint Blockade
Sponsor: Abramson Cancer Center at Penn Medicine
Summary
The purpose of this study is to better understand how the treatment of cancer with immune checkpoint inhibitors (ICI) leads to the development of autoimmunity. Specifically, we wish to understand the genetics and immune system features that cause a subset of cancer patients treated with checkpoint inhibitor therapy to develop an immune-related adverse event (irAE).
Official title: Mechanisms of Immunotoxicology in Cancer Patients
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
600
Start Date
2020-02-24
Completion Date
2026-06-30
Last Updated
2026-01-08
Healthy Volunteers
No
Conditions
Locations (1)
University of Pennsylvania - Abramson Cancer Center
Philadelphia, Pennsylvania, United States